We acknowledge the comments by van den Anker concerning our clinical trial on propofol compared with the morphine, atropine, and suxamethonium regimen as induction agents for neonatal endotracheal intubation, and we are grateful for the opportunity to respond to his questions. van den Anker questions the rationale behind our dose of 2.5 mg/kg and how a clinical trial was conducted without previous information on the pharmacokinetics of propofol in neonates. We agree that there is a need for more neonatal pharmacokinetics studies on propofol, but we think that there is a reasonable existing body of evidence on propofol pharmacokinetics on pregnant women and their newborns2–4  and children to warrant conduction of randomized, controlled trials. Dailland et al, Gin et al, and others3,4  have reported on placental transfer, breast milk concentrations, and early neonatal effects of propofol, and these studies suggested...

You do not currently have access to this content.